EP3764988A4 - Gelbildende polypeptide - Google Patents

Gelbildende polypeptide Download PDF

Info

Publication number
EP3764988A4
EP3764988A4 EP19768400.4A EP19768400A EP3764988A4 EP 3764988 A4 EP3764988 A4 EP 3764988A4 EP 19768400 A EP19768400 A EP 19768400A EP 3764988 A4 EP3764988 A4 EP 3764988A4
Authority
EP
European Patent Office
Prior art keywords
gel
forming polypeptides
polypeptides
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19768400.4A
Other languages
English (en)
French (fr)
Other versions
EP3764988A1 (de
Inventor
Sheau Yu Teddy Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adepthera LLC
Original Assignee
Adepthera LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adepthera LLC filed Critical Adepthera LLC
Publication of EP3764988A1 publication Critical patent/EP3764988A1/de
Publication of EP3764988A4 publication Critical patent/EP3764988A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19768400.4A 2018-03-15 2019-03-14 Gelbildende polypeptide Pending EP3764988A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862643593P 2018-03-15 2018-03-15
PCT/US2019/022275 WO2019178359A1 (en) 2018-03-15 2019-03-14 Gel-forming polypeptides

Publications (2)

Publication Number Publication Date
EP3764988A1 EP3764988A1 (de) 2021-01-20
EP3764988A4 true EP3764988A4 (de) 2022-04-20

Family

ID=67907279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19768400.4A Pending EP3764988A4 (de) 2018-03-15 2019-03-14 Gelbildende polypeptide

Country Status (3)

Country Link
EP (1) EP3764988A4 (de)
CN (1) CN111885999A (de)
WO (1) WO2019178359A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物
CN110818790A (zh) * 2019-10-31 2020-02-21 成都圣诺生物制药有限公司 一种替莫瑞林的制备方法
CN113577014B (zh) * 2020-12-30 2023-03-24 广州图微科创生物科技有限公司 医疗器械、水凝胶及其制备方法与应用
CN114181284A (zh) * 2021-11-17 2022-03-15 成都赛恩贝外科学研究院 纳米短肽drf3在药物、nk细胞载体和生物医学的应用
CN114214280B (zh) * 2021-12-20 2022-11-29 南开大学 一种利用自组装多肽衍生物水凝胶培养细胞球体的方法、一种细胞球体及其应用
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
CN116270974B (zh) * 2023-03-09 2024-03-12 湖南大学 一种组合物、阿柏西普递送系统和制备方法
CN117511851B (zh) * 2024-01-03 2024-03-26 中国肉类食品综合研究中心 水凝胶支架在细胞培育肉制备中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
US5998367A (en) * 1991-03-08 1999-12-07 Amylin Corporation Pramlintide pro H-amylin salts and compositions
US20050261179A1 (en) * 2002-10-04 2005-11-24 The Government Of The United States Of America Vasoregulating compounds and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE432689T1 (de) * 2002-03-04 2009-06-15 Ipsen Pharma Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MX362028B (es) * 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
CN105079783B (zh) * 2014-05-22 2018-06-19 清华大学深圳研究生院 药物组合物及其制备方法和用途
DE102015000363A1 (de) * 2015-01-20 2016-07-21 Emc Microcollections Gmbh Neue modular funktionalisierbare Peptid-Hydrogele
WO2017139154A1 (en) * 2016-02-09 2017-08-17 Adepthera Llc Dosing and use of long-acting clr/ramp agonists
CN107412150B (zh) * 2017-07-16 2019-07-09 常州大学 一种用于包裹药物的多肽水凝胶的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998367A (en) * 1991-03-08 1999-12-07 Amylin Corporation Pramlintide pro H-amylin salts and compositions
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
US20050261179A1 (en) * 2002-10-04 2005-11-24 The Government Of The United States Of America Vasoregulating compounds and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELGERSMA RONALD C. ET AL: "Synthesis and structural investigations of N-alkylated [beta]-peptidosulfonamide-peptide hybrids of the amyloidogenic amylin(20-29) sequence: implications of supramolecular folding for the design of peptide-based bionanomaterials", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 4, no. 19, 1 January 2006 (2006-01-01), pages 3587 - 3597, XP055866902, ISSN: 1477-0520, DOI: 10.1039/B606875H *
See also references of WO2019178359A1 *
SUTTER ET AL: "Recombinant gelatin hydrogels for the sustained release of proteins", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 3, 22 May 2007 (2007-05-22), pages 301 - 312, XP022087330, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.03.003 *

Also Published As

Publication number Publication date
CN111885999A (zh) 2020-11-03
WO2019178359A1 (en) 2019-09-19
EP3764988A1 (de) 2021-01-20

Similar Documents

Publication Publication Date Title
EP3856764A4 (de) Maskierte cytokin-polypeptide
EP3803740A4 (de) Blockchain-überwachung
EP3801265A4 (de) Uroflowmeter
EP3764988A4 (de) Gelbildende polypeptide
EP3784463A4 (de) Fluorsulfone
EP3813861A4 (de) Heparin-assoziierte polypeptide und deren verwendung
EP3802565A4 (de) Polypeptide
EP3721129A4 (de) Cryosphäre
AU2019350356A1 (en) Arginase1 polypeptides
EP3870698A4 (de) Antipathogene polypeptide
EP3876716A4 (de) Kryoträger
EP3834079A4 (de) Konfiguration aus mehreren fragen und mehreren antworten
EP3760901A4 (de) Dichtungsstruktur
EP3898652A4 (de) Auf mitochondrien abzielende peptide
EP3858868A4 (de) Polypeptidzusammensetzung
EP3792349A4 (de) Peptidmakrozyklase
EP3871913A4 (de) Mobiles objekt
EP3787554A4 (de) Stenttransplantat
EP3738602A4 (de) Zytozid
EP3608631A4 (de) Kompass
AU2018901430A0 (en) Modified polypeptides
AU2018904117A0 (en) Polypeptides and uses thereof
EP3791184A4 (de) Immunreaktive polypeptide
EP3822397A4 (de) Komplex
AU2018101027A4 (en) PadPay

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/02 20060101ALI20211215BHEP

Ipc: A61K 47/42 20170101ALI20211215BHEP

Ipc: A61K 38/16 20060101ALI20211215BHEP

Ipc: A61K 9/06 20060101ALI20211215BHEP

Ipc: A61K 9/00 20060101ALI20211215BHEP

Ipc: C07K 7/06 20060101ALI20211215BHEP

Ipc: C07K 14/47 20060101ALI20211215BHEP

Ipc: C07K 14/585 20060101ALI20211215BHEP

Ipc: C07K 14/575 20060101AFI20211215BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220321

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/02 20060101ALI20220315BHEP

Ipc: A61K 47/42 20170101ALI20220315BHEP

Ipc: A61K 38/16 20060101ALI20220315BHEP

Ipc: A61K 9/06 20060101ALI20220315BHEP

Ipc: A61K 9/00 20060101ALI20220315BHEP

Ipc: C07K 7/06 20060101ALI20220315BHEP

Ipc: C07K 14/47 20060101ALI20220315BHEP

Ipc: C07K 14/585 20060101ALI20220315BHEP

Ipc: C07K 14/575 20060101AFI20220315BHEP